(Note: NeuroPace upsized its IPO at pricing on April 21, 2021: 6 million shares, up from 5.31 million shares in the prospectus, were priced at $17 – the top of its $15-to-$17 range. The official pricing of the IPO was postponed to Wednesday night, April 21, from its original timing on Tuesday, April 20, after the company said in SEC filings that it had received an inquiry from the Commission on Foreign Investment in the U.S.)

We are a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. Our novel and differentiated RNS System is the first and only commercially available brain-responsive neuromodulation system that delivers personalized real-time treatment at the seizure source. By continuously monitoring the brain’s electrical activity, recognizing patient-specific abnormal electrical patterns, and responding in real time with imperceptible electrical pulses to prevent seizures, our RNS System is programmed by clinicians to deliver the precise amount of therapy when and where it is needed and provides exceptional clinical outcomes with approximately three minutes of stimulation on average per day. Our RNS System is also the only commercially available device that records continuous brain activity data and allows clinicians to monitor patients not only in person, but also remotely, providing them the data they need to make more informed treatment decisions, thus optimizing patient care. We believe the therapeutic advantages of our RNS System, combined with the insights obtained from our extensive brain data set, offer a significant leap forward in epilepsy treatment.

As of Dec. 31, 2020, over 3,000 patients have received our RNS System. We believe our compelling body of long-term clinical data, demonstrating continuous improvement in outcomes over time, will support the continued adoption of our RNS System among the approximately 575,000 adults in the United States with drug-resistant focal epilepsy. Over time, we plan to seek indication expansion more broadly for use across the entire population of about 1.2 million drug-resistant epilepsy patients in the United States; we may seek to expand our operations to reach the approximately 16.5 million drug-resistant epilepsy patients globally.